Markets opened higher this morning as Canadian and U.S. equities extended gains into the holiday week, supported by optimism around a Santa rally. The TSX is up 0.18%, while the Venture Index is also higher. In the U.S., the Dow and Nasdaq are advancing, with the S&P 500 hitting a new record as traders position for year-end. London’s FTSE is modestly higher as global markets remain steady ahead of a shortened trading day.
Commodities are mixed: gold is holding near record highs above $4,480, copper is sharply higher, and oil is steady amid geopolitical tensions. Natural gas is under pressure, while Bitcoin trades slightly lower. Headlines today spotlight energy and biotech, with BP selling a majority stake in its Castrol business and Agios Pharma jumping on expanded FDA approval for its blood disorder drug.
Market numbers
TSX: Up (+0.18%), 32,058.73
TSXV: Up (+0.52%), 990.68
DOW: Up (+0.16%), 48,442.42
NASDAQ: Up (+0.50%), 25,587.83
FTSE: Up (+0.22%), 9,894.00
In the headlines
- BP Divests Castrol Stake: BP (NYSE:BP) will sell a majority stake in its Castrol lubricants business for $6 billion, streamlining operations and focusing on energy transition priorities.
- Agios Pharma Surges: Agios Pharmaceuticals (NDAQ:AGIO) shares jumped after the U.S. FDA expanded approval for its blood disorder drug, boosting growth prospects in rare disease treatments.
Currencies
USD: Up (+0.10%), $0.7310
GBP: Up (+0.17%), $0.5410
EUR: Up (+0.16%), $0.6203
JPY: Down (-0.07%), ¥114.061
AUD: Down (-0.01%), $0.91688
Bitcoin: Down (-0.30%), 119,371.90 CAD
(Conversion to C$1)
Commodities
Copper: Up (+0.80%), $5.61878
Gold: Up (+0.01%), $4,484.93
WTI: Up (+0.17%), $58.755
Natural Gas: Down (-3.55%), $3.804
To stay up-to-date on all of your market news head to Stockhouse.com.
Join the discussion: Find out what everybody’s saying about BP and Agios Pharma for December 24th, 2025, on Stockhouse’s stock forums and message boards.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.